TITLE

The new antifungals-- safe and effective

AUTHOR(S)
Gallagher, Jason C.; Kauffman, Carol A.; Perfect, John
PUB. DATE
June 2005
SOURCE
Patient Care;Jun2005, Vol. 39 Issue 6, p41
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Discusses the advantages and indications of several antifungal agents. Reasons that the increased incidence of fungal infections shows no sign of decline or leveling of; Alternatives to amphotericin B deoxycholate; Infections caused by fungi, eukaryotes that are more complex organisms than bacteria; Main classes of systemic antifungal drugs. INSETS: Article at a glance;Beware the wide range of drug interactions.
ACCESSION #
17407125

 

Related Articles

  • Antimicóticos de uso sistémico: ¿Con que opciones terapéuticas contamos? G., ANA MARÍA RIVAS; CARDONA-CASTRO, NORA // CES Medicina;2009, Vol. 23 Issue 1, p61 

    The prevalence of invasive fungal infections has increased over the past three decades owing to the increasing numbers of immunocompromised hosts. For many years, amphotericin B and flucytosine were the only available antifungal agents for invasive fungal infections. Fortunately, the antifungal...

  • Combination Antifungal Therapy for Invasive Aspergillosis: Utilizing New Targeting Strategies. Steinbach, William J. // Current Drug Targets - Infectious Disorders;Sep2005, Vol. 5 Issue 3, p203 

    The optimal therapy for invasive aspergillosis (IA) is unknown, and there is little agreement on the exact antifungal management of IA. The previously stagnant landscape of antifungal choices for IA is rapidly changing with newer antifungals and newer targets. While amphotericin B has...

  • Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Girois, S. B.; Chapuis, F.; Decullier, E.; Revol, B. G. P. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2006, Vol. 25 Issue 2, p138 

    Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections; however, it is associated with significant toxicities that limit its use. Other systemic antifungal agents have been developed to improve tolerability while maintaining the efficacy profile of...

  • High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Lafaurie, M.; Lapalu, J.; Raffoux, E. // Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 4, p150 

    In this study, the authors sought to determine the efficacy of antifungal agents for preventing breakthrough invasive aspergillosis (IA) in a cohort of patients with persistent fever and neutropenia who received empirical antifungal therapy. Caspofungin was the most prescribed antifungal agent,...

  • Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients. Wingard, John R. // Clinical Infectious Diseases;7/15/2004 Supplement 1, Vol. 39, pS38 

    Persistent or recurrent unexplained fever in neutropenic patients receiving antibiotics can be caused by invasive fungal infections, which are often difficult to diagnose. Early trials of empirical antifungal therapy with amphotericin B deoxycholate (AmB) documented reductions in the frequency...

  • Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5-Fluorocytosine for Treatment of Invasive Candidiasis. Hope, William W.; Warn, Peter A.; Sharp, Andrew; Reed, Paul; Keevil, Brian; Louie, Arnold; Denning, David W.; Drusano, George L. // Journal of Infectious Diseases;8/15/2005, Vol. 192 Issue 4, p673 

    The strategy of combining antifungal drugs in a treatment regimen may improve the outcome of invasive candidiasis. Using a well-validated pharmaco dynamic murine model of invasive candidiasis, we defined the effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine...

  • Fungal metabolism in host niches.  // Journal of Invasive Fungal Infections;2010, Vol. 3 Issue 4, p138 

    The inhibition of primary metabolism is a promising therapeutic strategy for combating fungal infections. Fungal metabolism is dynamic and varies over the course of pathogenesis. Knowledge about the metabolic requirements of fungi during infection could assist in the development of new classes...

  • Therapy for fungal diseases: opportunities and priorities.  // Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 3, p118 

    The present authors discuss the basic principles governing the use of each of five classes of antifungal agents, offering an insight into the challenges that are currently faced by clinicians treating fungal infections. Furthermore, they highlight some priorities for the development of novel...

  • In vitro effectiveness of antifungal lock solutions on catheters infected with Candida species. Öncü, Serkan // Journal of Infection & Chemotherapy (Springer Science & Business;Oct2011, Vol. 17 Issue 5, p634 

    The antibiotic lock technique involves filling the catheter lumen with an antibiotic solution and allowing it to dwell for sufficient time to sterilize the infected device. However, antifungal therapy for treating catheter-related fungal infection in this setting is unknown. In this study, the...

Share

Read the Article

Courtesy of NEW JERSEY STATE LIBRARY

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics